Myeloma is a cancer of the plasma cells, which normally produces anitibodies to help fight infections. Left untreated, myeloma can interfere with production of normal blood cells and cause serious complications in bones and kidneys. When these cancerous cells form tumors throughout the body, it is classified as multiple myeloma.
As one of a handful of institutes to attain the elite designation of
Comprehensive Cancer Center by the National Cancer Institute,
City of Hope is acknowledged as a leader in the research and treatment of myeloma and related diseases. With our decades of experience, specialized therapy protocols and extensive program of clinical trials, newly diagnosed or relapsed myeloma patients can find a treatment regimen that is tailored to their disease and gives them the best chance for survival.
City of Hope is the only southern California member of the Multiple Myeloma Research Consortium, a collaboration of research organizations focused on rapidly bringing the most promising multiple myeloma treatments to patients.
Our physicians treat myeloma and related plasma cell diseases, including:
Plasmacytoma: a single tumor comprised of cancerous plasma cells
Waldenstrom macroglobulinemia: a disease with features of myeloma and non-Hodgkin lymphoma, characterized by high levels and buildup of monoclonal protein (M protein)
Monoclonal gammopathy of undetermined significance (MGUS): a slight overgrowth of plasma cells that can lead to myeloma or lymphoma
City of Hope has long been a leader in developing promising new combinations of chemotherapy drugs, stem cell transplant procedures, radiation treatments and therapeutic options.
City of Hope pioneered innovative transplant regimens that have improved the cure rate for patients with myeloma and other hematologic disorders.
City of Hope performs both autologous (using cells from the patient) and allogeneic (using cells from a matched donor) stem cell transplants.
Our transplant program is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), the standard of excellence for blood and bone marrow transplant programs in the United States.
In addition to our world-renowned transplant program, City of Hope also offers the broadest range of therapeutic options available for treating myeloma, including adoptive T-cell therapy, helical tomotherapy and monoclonal antibody therapy.
Myeloma patients at City of Hope may also qualify to receive their transplant in an outpatient setting, giving them the option to go home after their treatments instead of staying in the hospital overnight.
In collaboration with other departments and cancer centers, City of Hope’s myeloma program has an active portfolio of myeloma clinical trials
studying novel treatments against the cancer, including trials of new chemotherapy, immunotherapy and radiation therapy that are more effective against the disease and/or less toxic to the patient. Many of these promising therapies are only available to patients being treated at the City of Hope.
City of Hope physicians and researchers are particularly involved in new cancer drugs and drug combinations that can target and attack relapsed myeloma, which are or have become resistant to first-line treatment.
We are also actively involved in survivorship research to ensure that our myeloma patients have a minimal chance of developing long-term effects from their disease or treatment.
If you have been diagnosed with myeloma or are looking for a second opinion consultation about your treatment, find out more about
becoming a patient
or contact us at 800-826-HOPE.